Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Editor

Personal info

View

About

Terms

Javascript disabled

Please enable Javascript support in your browser to use this application.

Instructions on how to enable JavaScript on different browsers can be found here: http://www.google.com/support/bin/answer.py?answer=23852.

[edit this page]

Gottfries, C.G.

Pharmacological treatment strategies in Alzheimer type dementia.

Substitution of cholinergic drugs in the treatment of Alzheimer type dementia (AD/SDAT) has hitherto not been very successful. Accumulating data indicate that monoamines are disturbed in AD/SDAT patients. The selective 5-hydroxytryptamine re-uptake blocker, Citalopram, has proven effective in reducing overactivity in the hypothalamic-pituitary-adrenal axis and in improving emotional disturbances in patients with dementia. Efforts to substitute the dopaminergic system have hitherto been negative. Neither has treatment with neuropeptides made any breakthrough in the treatment of demented patients. Nootropics are drugs like Piracetam that are assumed to activate the metabolism of the neurons. Although these drugs have proven effects on the CNS in animal experiments these effects cannot be reproduced in man to the same extent. A subgroup of patients with late onset dementia has reduced concentrations of vitamin B12 and atrophic gastritis. Whether the vitamin B12 deficiency or deficiency of other essential nutrients, is of importance for the brain dysfunction is not clarified. Treatment trials with vitamin B12, folic acid, S-adenosylmethionine and acetyl L-carnitine are in progress. GM1 has proven effect in peripheral nerve damage. GM1 seems not to penetrate the blood brain barrier. If the effect of GM1 and eventually nerve growth factors should be tested in patients with dementia the administration must obviously be directly into the ventricular space.[1]

References

Pharmacological treatment strategies in Alzheimer type dementia. Gottfries, C.G. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. (1990) [Pubmed]

Annotations and hyperlinks in this abstract are from individual authors of WikiGenes or automatically generated by the WikiGenes Data Mining Engine. The abstract is from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenes Open Access Licence Privacy Policy Terms of Use apsburg

The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.